Commercialization of R&D Pipelines and Establishment of Post-Launch Royalty Revenue
First written in FY2022. 13 of 18 entries say "Advanced", first in FY2023-Q1. Latest entry: 2026-08-12.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「A clinical trial conducted by Maruho Co., Ltd. moved to an early Phase II clinical trial during the current fiscal year, and the Company received a milestone payment. Under the contractual structure, the Company will continue to receive milestone income in stages as development progresses, followed by royalty income once the product is launched. The program is positioned as one of the Company’s core pipelines in the dry-eye area.」
In addition to TLM-001’s transition to an early Phase II trial and receipt of a milestone payment, the commercialization stage of multiple pipelines is advancing, including the start of a clinical study for TLM-017 and progress of TLM-003 into Phase II trials in Japan and overseas. - FY2026-H1AdvancedAnnual report
「Based on these R&D activities, business development efforts are under way to out-license TLG-005, a medical device for brain diseases applying violet-light technology, through negotiations with multiple companies in Japan and overseas. Global licensing negotiations for TLG-001, a medical device for suppressing the progression of myopia, are also continuing with multiple overseas operating companies in Western markets. Discussions are also actively under way with prospective international partners regarding the new pharmaceutical pipelines TLM-017 and TLM-023.」
Out-licensing and licensing negotiations for TLG-005, TLG-001, and the new pharmaceutical pipelines TLM-017 and TLM-023 are under way with multiple companies in Japan and overseas and prospective international partners. - FY2025-H1AdvancedAnnual report
「In September, the Company entered into a patent licensing agreement covering specific regions with Shenyang Xingqi Pharmaceutical Co., Ltd., a major Chinese ophthalmic pharmaceutical manufacturer. Through this agreement, we believe we will be able to make treatments based on patents held by the Company widely available in China.」
It entered into a patent licensing agreement with a major Chinese ophthalmic pharmaceutical manufacturer, marking progress toward commercializing and out-licensing patent-based treatments for provision in China. - FY2024AdvancedAnnual report
「In business development, enrollment of subjects in the TLG-001 confirmatory clinical trial was completed, and the Company achieved a milestone under the license agreement with JINS HOLDINGS Inc. In addition, it entered into an intellectual property license agreement with Rohto Pharmaceutical Co., Ltd. covering intellectual property rights and R&D results related to eye drops held, or to be held, by the Company, and began developing a new eye drop, TLM-018.」
For TLG-001, the Company achieved a milestone under the license agreement and progressed to a new licensing agreement with Rohto Pharmaceutical and the launch of TLM-018 development in the eye-drop business. - FY2023RestatedAnnual report
「The Company’s envisioned future business model is to generate royalty income from sales of products launched by partner companies through joint development.」
It continues to present a future model of generating post-launch royalty income through joint development and licensing. It also states that it has not yet reached the stage of recording stable royalty income. - FY2023-Q3AdvancedAnnual report
「In business development, following the commencement of the confirmatory clinical trial for TLG-001, a medical device for suppressing myopia using violet-light technology, the Company achieved a milestone under a domestic licensing agreement and entered into a new licensing agreement covering North and South America. For TLM-003, an eye drop that suppresses the progression of myopia, it also achieved a milestone under the joint research and development agreement and entered into a new licensing agreement covering the United States and Europe.」
For TLG-001, the Company achieved a milestone under a domestic licensing agreement and entered into a new licensing agreement covering North and South America. For TLM-003, it also achieved a milestone under the joint research and development agreement and entered into a new licensing agreement covering the United States and Europe, marking further progress in commercializing and out-licensing the pipeline. - FY2023-Q2AdvancedAnnual report
「In business development, the Company achieved a milestone under the TLG-001 licensing agreement based on the commencement of the confirmatory clinical trial, as well as a milestone under the joint research and development agreement for TLM-003, an eye drop that suppresses the progression of myopia.」
In addition to TLG-001, the Company reported achievement of a milestone under the joint research and development agreement for TLM-003, indicating progress toward commercializing the pipeline. - FY2023-Q1AdvancedAnnual report
「In business development, the Company achieved a milestone under the TLG-001 licensing agreement based on the commencement of the confirmatory clinical trial.」
It actually achieved a milestone under the licensing agreement, marking concrete progress toward commercializing the pipeline. - FY2022First statedAnnual report
「The Company’s envisioned future business model is to leverage its R&D capabilities and generate royalty income from products launched through joint development with other companies.」
A future model of generating post-launch revenue through joint development and licensing.